Welcome to our dedicated page for AtaiBeckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
AtaiBeckley Inc. director Amir H Kalali received a stock option grant as part of his board compensation. The option covers 121,968 shares of common stock with a $4.50 exercise price and expires on June 4, 2036. It vests on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to his continued service on the board.
AtaiBeckley Inc. director Andrea Heslin Smiley received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, contingent on continued board service.
AtaiBeckley Inc. director Sabrina Martucci Johnson received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. The options expire on June 4, 2036 and vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to continued board service.
AtaiBeckley Inc. reported the results of its annual stockholder meeting. As of the April 9, 2026 record date, 366,916,896 common shares were outstanding and entitled to vote, and 203,908,561 shares were represented at the meeting, constituting a quorum.
Stockholders elected Class I directors Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
AtaiBeckley Inc. reported that it will participate in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference, the Oppenheimer CNS and Neuro-Muscular Summit, the 7th Annual HCW Neuro Perspectives Hybrid Conference, and UBS Virtual CNS Day. Management plans to discuss program updates, including initiation of the BPL-003 Phase 3 pivotal ReConnection program, along with other topics. Webcasts for certain events will be available through the company’s investor relations website. The communication is furnished as a Regulation FD disclosure and is accompanied by standard cautionary language about forward-looking statements and related risks.
AtaiBeckley Inc. reported a wider loss for the three months ended March 31, 2026 as it continues to fund clinical-stage mental health programs. Total revenue was $0.95 million, mainly from Nualtis licensing and research services, compared with $1.56 million a year earlier.
Research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, driving a net loss attributable to stockholders of $29.8 million, or $0.08 per share, versus $26.4 million and $0.15 per share in 2025. Cash and cash equivalents were $43.1 million and short-term securities $166.8 million as of March 31, 2026, and the company states this liquidity should fund operations for at least 12 months.
AtaiBeckley Inc. reported first quarter 2026 results showing continued investment in its mental health pipeline and a solid cash position. Revenue was $954 thousand, while research and development expenses rose to $17.4 million and general and administrative expenses to $14.4 million, reflecting higher clinical and personnel costs.
Net loss attributable to stockholders was $29.8 million, compared with $26.4 million a year earlier, as the company advances BPL-003 into a Phase 3 ReConnection program for treatment-resistant depression and continues Phase 2 development for VLS-01 and EMP-01. Cash, cash equivalents and short-term securities totaled $209.9 million as of March 31, 2026, and are expected to fund operations into 2029.
AtaiBeckley Inc. Chief Medical Officer Craig Kevin James executed a pre-planned option exercise-and-sale transaction involving company common stock. On the reported date, he sold 42,579 shares of common stock in an open-market sale at $5.00 per share and exercised stock options covering a total of 42,579 shares at exercise prices of $1.84 and $1.50 per share. The filing states that these option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on December 19, 2025, indicating the trades were pre-arranged rather than timed discretionarily.
AtaiBeckley Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. The proxy seeks approval to elect three Class I directors — Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley — to terms ending at the 2029 annual meeting, and to ratify Deloitte & Touche LLP as independent auditor for 2026.
Holders of 366,916,896 common shares outstanding as of April 9, 2026 are entitled to one vote per share and may vote online, by telephone, or by mail. The company highlights its recent strategic combination of atai Life Sciences and Beckley Psytech and redomiciliation to Delaware, a classified nine‑member board, standard Nasdaq-based independence, and policies covering clawbacks, anti‑hedging, insider trading, and related‑party approvals.
The proxy details security ownership, including a 15.0% stake held by Apeiron Investment Group Ltd., board and committee composition, meeting procedures for the fully virtual format, auditor fees, and prior capital raises in 2025 via a public offering and PIPE financing that included significant Apeiron participation.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Rule 144 notice to sell 42,579 shares of Common Stock on 04/20/2026, described as resulting from an exercise of stock options and to be settled for cash. The filing lists the transaction as through an issuer-directed exercise.
The excerpt also discloses a prior 10b5-1 sale by Kevin James Craig of 100,000 shares on 03/20/2026 for proceeds of $355,480.00.